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Abstract: A reduced content of alveolar elastic fibers is a key feature of COPD lung. Despite 
continued elastogenic potential by alveolar fibroblasts in the lung affected by COPD, repair 
of elastic fibers does not take place, which is due to increased levels of the chondroitin sulfate 
proteoglycan versican that inhibits the assembly of tropoelastin into fibers. In this study, primary 
pulmonary fibroblast cell lines from COPD and non-COPD patients were treated with a small 
interfering RNA (siRNA) against versican to determine if knockdown of versican could restore 
the deposition of insoluble elastin. Versican siRNA treatment reduced versican expression and 
secretion by pulmonary fibroblasts from both COPD and non-COPD patients (P0.01) and 
significantly increased deposition of insoluble elastin in the COPD cell cultures (P0.05). 
The treatment, however, did not significantly affect production of soluble elastin (tropoelastin) 
in either the COPD or non-COPD cell cultures, supporting a role for versican in inhibiting 
assembly but not synthesis of tropoelastin. These results suggest that removal or knockdown 
of versican may be a possible therapeutic strategy for increasing deposition of insoluble elastin 
and stimulating repair of elastic fibers in COPD lung.
Keywords: pulmonary fibroblasts, COPD, elastin, versican
Introduction
COPD is characterized by irreversible airflow obstruction in the small airways,1,2 is 
thought to be primarily due to emphysematous changes in which there is loss of elastic 
fibers in alveolar walls and subsequent destruction of the alveoli, which in turn results 
in the loss of alveolar attachments to the small airways. This is believed to lead to the 
collapse of the small airways on expiration, which then leads to airflow obstruction.3 The 
disease is ongoing, and repair mechanisms appear to be largely inhibited. Our previous 
research provides support for the idea that loss of repair mechanisms may be important 
in the development and progression of COPD. The lung tissues from patients undergo-
ing lobectomy for bronchial carcinoma were analyzed immunohistochemically. Some 
of these individuals (who were current or ex-smokers) had normal lung function, while 
the remainder had mild-to-moderate COPD. We found that elastin content was signifi-
cantly decreased in the lung tissue of patients with COPD and as a function of forced 
expiratory volume in 1 second (FEV
1
)4 and, correspondingly and also as a function of 
FEV
1
, an increase in the matrix proteoglycan versican.5 This is relevant because versican 
has been shown to inhibit the assembly of elastic fibers in cultures of fibroblasts6 and 
smooth muscle cells7 and in vessels in vivo.7,8 Our findings on lung are consistent with 
the idea that patients with COPD have a reduced capacity to form new elastic fibers, 
despite the ability to synthesize the soluble elastin precursor tropoelastin.9
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Versican is a large chondroitin sulfate (CS) proteoglycan 
with a molecular mass of 1,000 kDa.10 It is secreted by 
numerous cells, including lung fibroblasts, and interacts with 
various binding partners.11 There are at least four isoforms, 
such as V0, V1, V2, V3; the central domain of V0 contains 
two GAG-binding domains, α and β; V1 has only the GAG-β 
domain; V2 has only the GAG-α domain; and V3 is void of 
both GAG attachment domains.12 The three isoforms that 
possess GAG chains (V0, V1, and V2) inhibit the assembly 
of tropoelastin onto the microfibrillar scaffold of elastic 
fibers by binding to EBP. EBP is a receptor that chaperones 
tropoelastin through the golgi to the cell surface, but in the 
presence of the CS-containing versican isoforms or CS chains 
alone, the tropoelastin is prematurely released prior to assem-
bly and cross-linking on the microfibrillar scaffold.13
In a previous study, we reported that lung parenchyma 
from patients with mild-to-moderate COPD showed pro-
gressively increased immunostaining for versican and 
correspondingly decreased immunostaining for EBP, with 
decreasing FEV
1
.5 In that study, we proposed that the 
elevated levels of the large CS-containing versican variants 
may explain the lack of repair of elastic fibers in the lungs 
of patients with moderate COPD.
In a subsequent study, pulmonary fibroblasts were cultured 
from explants of lung tissue obtained from 20 patients under-
going surgery for resection of bronchial carcinoma. We found 
a significant increase in the expression of versican messenger 
RNA (mRNA) by the COPD fibroblasts compared with non-
COPD controls. Secreted versican levels were also increased 
in the supernatants from the COPD fibroblasts compared with 
controls.13 Soluble elastin was also increased in the COPD 
cultures, but there was, however, no difference between the 
COPD and control groups in the levels of insoluble elastin, 
indicating that the increased secretion of tropoelastin by COPD 
fibroblasts did not result in elastin deposition, consistent with 
the increase in versican expression and secretion. Versican 
may thus play a key role in maintaining the obstructive state 
and inhibiting repair of COPD lung by interfering with the 
assembly of elastic fibers. Removal of versican may offer a 
novel strategy for stimulating effective repair.13
In this study, we have investigated the effect of a versican 
small interfering RNA (siRNA) on elastogenesis and show 
that knockdown of versican increases deposition of insoluble 
elastin by pulmonary fibroblasts from COPD patients.
Methods and materials
Pulmonary fibroblasts
A total of 12 lines of cryopreserved and characterized 
pulmonary fibroblasts were cultured from lung tissues of 
12 patients obtained at the time of surgery for bronchial 
carcinoma. Six patients of the non-COPD group had nor-
mal lung function (FEV
1
 80% and FEV
1
/vital capacity 
[VC] 0.7) and six patients of the COPD group had mild-
to-moderate COPD (FEV
1
 80% predicted and FEV
1
/
VC 0.7). For each patient, fibroblasts were initially 
obtained by explant culture from peripheral portions of the 
resected lobe, remote from the tumor. All cell lines were 
evaluated immunohistochemically (vimentin) to confirm 
that 99% of the cells were fibroblasts. Cells of passages 
3–5 were used for experiments. The study was approved 
by the Northern X Regional Ethics Committee, Ministry of 
Health. Written informed consent for permission to use the 
lung tissue for research was obtained preoperatively.
Culture and sirna treatment
All cells lines were cultured to confluence over 7 days in 
24-well plates of the culture medium Dulbecco’s Modified 
Eagle’s Medium (Thermo Fisher Scientific, Waltham, MA, 
USA) supplemented with 10% fetal calf serum, penicillin 
(100 ng/mL), and streptomycin (100 ng/mL). Confluent 
cultures were treated with siRNA as follows. Stealth siRNA 
molecule–Lipofectamine® complexes were prepared just 
prior to transfection, based on manufacturer’s instructions 
(Stealth siRNAs for versican HSS175421, HSS175422, 
HSS175423 [Thermo Fisher Scientific], targeting all iso-
forms). Lipofectamine® (Thermo Fisher Scientific) was 
gently mixed before use and added in a ratio of 1:100 with 
Opti-MEM® Medium (Thermo Fisher Scientific) without 
serum. Stealth™ RNA interference was also added into the 
same medium at a ratio of 900 pmol/1.5 mL. The complex 
solution was mixed gently and incubated for 15 minutes at 
room temperature to allow for complex formation. In all, 
0.5 mL of the complex solution and 1 mL of normal cultural 
medium (without serum) were added to each well. The plate 
was mixed gently by rocking. The cells were then incubated 
for 24 hours at 37°C in a CO
2
 incubator, and the complex 
medium replaced by normal cultural medium for these wells 
continued for subsequent treatments.
For each of the 12 cell lines, four wells were treated only 
once with the transfection solution (on day 8), four wells 
were treated on day 8 and again 1 week later (on day 15), 
and four wells were treated on days 8, 15 and 22. At each 
time point, two of the treated wells and duplicate untreated 
control wells were harvested 24 hours after each transfection 
(on days 9, 16 and 23) for gene expression analysis. At the 
same time, the medium was collected for determination of 
protein levels of versican and tropoelastin (soluble elastin). 
To determine the effect of siRNA treatment on insoluble 
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elastin levels, duplicate wells for each of the 12 lines were 
treated three times on days 8, 15 and 22, with medium 
changes on days 9, 16 and 23 and cultured until day 28, to 
allow time for deposition of elastin.7,8 Both medium and cell 
layers were collected and pooled for analysis of insoluble 
elastin levels. Duplicate untreated control cultures for each 
line were also collected on day 28.
mrna expression and protein levels
mRNA expression of versican and elastin was measured by 
real-time reverse transcription polymerase chain reaction 
SYBR Green system as described previously.13 The primer 
pairs used were as follows: elastin 5′-TCT GAG GTT CCC 
ATA GGT TAG GG-3′ (forward primer) and 5′-CTA AGC 
CTG CAG CAG CTC CT-3′ (reverse primer) and versican 1 
5′-CCC AGT GTG GAG GTG GTC TAC-3′ (forward 
primer) and 5′-CGC TCA AAT CAC TCA TTC GAC 
GTT-3′ (reverse primer). Tropoelastin levels and versican 
levels in culture supernatant were measured by Human 
Versican ELISA Kit (Cusabio) and Fastin Elastin Assay 
(Biocolor), respectively. Briefly, for versican levels, pre-
coated antibody specific for versican was provided onto a 
microplate. Standards and samples were pipetted into the 
wells, and versican present was bound by the immobilized 
antibody. After removing any unbound substances, a biotin-
conjugated antibody specific for versican was added to the 
wells. After washing, avidin-conjugated HRP was added 
to the wells. Following a wash to remove any unbound 
avidin–enzyme reagent, a substrate solution was added to 
the wells with color developed in proportion to the amount 
of versican bound in the initial step. Color development 
was stopped, and the intensity of the color was measured. 
Insoluble elastin was determined by Fastin Elastin Assay 
according to the manufacturer’s instructions.
All statistical analyses were performed using GraphPad 
Prism v5.0, and one-way analysis of variance followed by 
Bonferroni post hoc test was performed to determine whether 
differences between groups were statistically significant. 
Duplicate values for each cell line at each time point for 
all determinations were averaged to provide an n=6 for the 
COPD lines and an n=6 for the non-COPD lines. Differences 
were considered significant at the level of P0.05.
Results
Versican expression and levels
Cultures of pulmonary fibroblasts from COPD and non-COPD 
patients were cultured for up to 4 weeks and treated on days 
8, 15, and 22 with versican siRNA. The cells were collected 
24 hours after each treatment for the measurement of versican 
mRNA levels. Prior to the first treatment, versican expres-
sion was slightly (P0.05) higher in fibroblasts from COPD 
patients compared to non-COPD control cultures. Following 
the first and second siRNA treatments, versican expression in 
the COPD group progressively decreased but did not reach 
significance until the third treatment (decreased by 24.1%; 
P0.01; Figure 1). Similarly, versican expression in the non-
COPD cultures was significantly reduced after the third treat-
ment compared to before treatment (P0.01; Figure 1).
Versican levels in the supernatant of cultured primary 
pulmonary fibroblasts were measured by enzyme-linked 
immunosorbent assay on days 9, 16 and 23. Versican levels 
were progressively reduced after the first, second and third 
versican siRNA treatments compared to the before treat-
ment level (Figure 2), and for both groups, the decrease 
Figure 1 Relative expression of versican mRNA by cultured lung fibroblasts from patients with COPD (n=6) and without COPD (non-COPD; n=6).
Notes: (A) Untreated confluent cultures from COPD and non-COPD patients sampled on day 9 compared to versican siRNA-treated (COPD-T and non-COPD-T) 
cultures. Cultures were treated only once on day 8. (B) Untreated and treated COPD and non-COPD cultures treated twice on days 8 and 15 and sampled day 16. 
(C) Untreated and treated COPD and non-COPD cultures treated three times on days 8, 15 and 22 and sampled day 23. Box plots show median, lower quartile and upper 
quartile values and ranges. Versican siRNA treatment suppressed versican expression in both COPD and non-COPD cell lines (P0.01).
Abbreviations: sirna, small interfering rna; mrna, messenger rna.
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in the versican levels reached significance after the third 
treatment (P0.05).
Tropoelastin expression and soluble and 
insoluble elastin levels
Versican siRNA treatment had no significant effect on tro-
poelastin mRNA expression by COPD and non-COPD cells 
(P0.05; Figure 3) and similarly due to variability within 
groups had no significant effect on soluble elastin (tropoelas-
tin) levels in either group (P0.05; Figure 4) out to 23 days. 
COPD lines treated three times with siRNA, on days 8, 15, 
and 22, followed by culture out to 28 days showed a significant 
increase in insoluble elastin content compared to untreated 
controls (P0.05). Insoluble elastin did not increase signifi-
cantly in the treated non-COPD group (Figure 5). The mean 
increase in insoluble elastin in the treated cultures of the COPD 
patients was 28.3% compared to the mean baseline value.
Discussion
COPD is characterized by loss of elastic fibers in alveolar 
walls and small airways, and the decrease in elastin cor-
relates with increase in disease severity as measured by 
FEV
1
.5 Similarly, and reciprocal to elastin content, increasing 
disease severity is associated with increased versican content 
in COPD lung. Importantly, changes in the EBP track with 
elastin. Hallgren et al14 and Larsson-Callerfelt et al15 have 
also reported that (distally derived) fibroblasts from COPD 
patients have higher versican production and proposed that 
the elevated versican levels may have a negative influence 
on the elastic recoil in COPD lung. Numerous experimental 
Figure 2 Versican levels in supernatants of cultured lung fibroblasts from patients with COPD (n=6) and without COPD (non-COPD; n=6).
Notes: Versican levels were determined in supernatants collected 24 hours after addition of the final siRNA treatment, on days 9, 16 and 23. Versican siRNA treatment 
suppressed versican levels in both COPD and non-COPD cell lines (P0.05). (A) Untreated confluent cultures from COPD and non-COPD patients sampled on day 9 compared 
to versican siRNA-treated (COPD-T and non-COPD-T) cultures. Cultures were treated only once on day 8. (B) Untreated and treated COPD and non-COPD cultures treated 
twice on days 8 and 15 and sampled day 16. (C) Untreated and treated COPD and non-COPD cultures treated three times on days 8, 15 and 22 and sampled day 23.
Abbreviation: sirna, small interfering rna.
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Figure 3 Relative expression of tropoelastin mRNA by lung fibroblasts from patients with COPD (n=6) and without COPD (non-COPD; n=6).
Notes: Message levels were determined 24 hours after the final siRNA treatment for each time period. The box plots are as for Figure 1. Versican siRNA treatment did 
not significantly affect tropoelastin expression in either the COPD or non-COPD cell lines. (A) Untreated confluent cultures from COPD and non-COPD patients sampled 
on day 9 compared to versican siRNA-treated (COPD-T and non-COPD-T) cultures. Cultures were treated only once on day 8. (B) Untreated and treated COPD and 
non-COPD cultures treated twice on days 8 and 15 and sampled day 16. (C) Untreated and treated COPD and non-COPD cultures treated three times on days 8, 15 and 
22 and sampled day 23.
Abbreviations: sirna, small interfering rna; mrna, messenger rna.
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studies have demonstrated the importance of versican, with 
its CS chains, as an inhibitor of the assembly of elastic 
fibers.6–9 High levels of versican likely play a key inhibitory 
role in the repair of COPD lung by interfering with the forma-
tion of new elastic fibers, and removal of versican may offer 
a new strategy for stimulating effective repair.
In this study, we show that versican siRNA treatment 
reduces versican mRNA expression (P0.01) and production 
(P0.05) in pulmonary fibroblasts from COPD and non-
COPD patients, does not significantly affect soluble elastin 
(tropoelastin) production in either the COPD or the non-
COPD cell lines (P0.05), and increases insoluble elastin 
levels in COPD (P0.05) but not non-COPD cell lines.
While the increase in insoluble elastin was modest (~30%), 
as was the decrease in secreted versican into the culture medium 
(~24.1%), these findings are consistent with the inhibition of 
EBP-mediated assembly of elastic fibers by versican. In this 
model, pericellular CS, as a component of versican, binds to 
EBP, an inactive variant of β-galactosidase, and causes the 
premature release of tropoelastin prior to assembly onto the 
microfibrillar scaffold of developing fibers.16 Knockdown of 
versican by siRNA reduces versican synthesis and secretion, 
as occurred for both COPD and non-COPD cell lines, and 
creates a more permissive environment at the cell surface for 
assembly of elastic fibers. The absence of a significant effect, 
notwithstanding variability, on tropoelastin mRNA and soluble 
elastin is not inconsistent with this model as these measures 
do not necessarily predict insoluble elastin content of tissues, 
which is determined by factors, including versican affecting 
assembly rather than synthesis. In some situations, notably 
in emphysematous lung tissue9 and in neointima of vessels 
following balloon angioplasty,17 tropoelastin message is sig-
nificantly elevated without increased elastin deposition.
The relatively small decrease in secreted versican 
(~24.1%) is consistent with the increase in insoluble elastin 
and may reflect inefficiency of knockdown by siRNA. The 
decrease in versican message was notably greater than the 
decrease in secreted versican. Message levels, however, 
across a wide range of organs and cells are often not strongly 
correlated with protein concentrations.18
Other studies have reported on the elastogenic effects of 
interference of versican expression. Huang et al19 reported 
that retroviral overexpression of a versican antisense sequence 
by smooth muscle cells significantly reduced versican 
production, induced a flattened morphology, reduced cell 
proliferation and migration, increased tropoelastin synthesis, 
increased EBP, and most importantly increased deposition of 
elastic fibers in long-term cultures and in vivo in neointima in 
a balloon catheter model of injured artery wall.19 Similarly, the 
Figure 4 Soluble elastin levels in the supernatants of cultures of fibroblasts from patients with COPD (n=6) and without COPD (non-COPD; n=6).
Notes: Soluble elastin levels were determined in supernatants collected 24 hours after the final siRNA treatments. Versican siRNA treatment did not significantly affect 
soluble elastin levels in either the COPD or non-COPD cell lines. (A) Untreated confluent cultures from COPD and non-COPD patients sampled on day 9 compared to 
versican siRNA-treated (COPD-T and non-COPD-T) cultures. Cultures were treated only once on day 8. (B) Untreated and treated COPD and non-COPD cultures treated 
twice on days 8 and 15 and sampled day 16. (C) Untreated and treated COPD and non-COPD cultures treated three times on days 8, 15 and 22 and sampled day 23.
Abbreviation: sirna, small interfering rna.
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Figure 5 Insoluble elastin levels in cultures of lung fibroblasts from patients with 
COPD (n=6) and without COPD (non-COPD; n=6).
Notes: Cultures were either not treated (COPD and non-COPD) or treated 
(COPD-T and non-COPD-T) three times (on days 8, 15 and 22) with versican siRNA. 
all cultures were maintained for 28 days to allow time for elastin deposition before 
collection of cell layers and media (pooled) for analysis. Versican siRNA treatment 
significantly increased insoluble elastin levels in the COPD cell lines (P0.05).
Abbreviation: sirna, small interfering rna.
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same group found that overexpression of versican variant V3, 
the variant lacking CS chains and chain-less biglycan induces 
similar changes7,20 and in particular reduces the amount of 
versican V0/V1 in the cell coat of smooth muscle cells in 
culture and in arterial wall, a change found to facilitate the 
assembly of elastic fibers. A caveat to using elastogenic tech-
nologies to restore elastin to lung is that excessive deposition 
of insoluble elastin could have a deleterious effect on lung 
expansion during inspiration; thus, if shown to be effective, 
then treatments may need to be titrated.
A further caveat to the study is the source of cells from 
patients with bronchial carcinoma, at a stage sufficient to 
warrant surgical resection. While the lung fibroblasts were 
cultured from parenchyma sourced at a distance from tumors, 
tumor cells produce versican21 and versican may be elevated 
in adjacent parenchyma.22 Fibroblasts, however, were sourced 
from subjects with and without COPD, but all with carcino-
mas. While we cannot discount differential effects between 
the groups due to variability in carcinoma morphology or 
metabolism between the two groups, the principal finding 
of increased insoluble elastin resulting from knockdown of 
versican remains regardless of the original stimuli to versican 
secretion by the parenchymal fibroblasts.
Conclusion
We report that siRNA knockdown of versican expression 
by primary pulmonary fibroblasts from patients with COPD 
inhibits production of versican and enhances the deposition 
of insoluble elastin. These results suggest that decreasing the 
amount of the large versican proteoglycans that are increased 
in COPD lung may offer a new strategy for stimulating effec-
tive repair of emphysematous lung.
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